18 active not recruiting. 18 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Active not recruiting 18 |
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Bone Scan: new trials by email Literature Review of Bone Scan trials Research Report on Bone Scan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Binimetinib, Biopsy Procedure, Biospecimen Collection - Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 199 | 2023-12-13 | 2026-08-21 |
| Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2023-03-30 | 2026-10-01 |
| Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial Atezolizumab, Biospecimen Collection, Bone Scan - Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 200 | 2023-03-24 | 2026-10-01 |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Anal Melanoma, Bladder Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 101 | 2022-08-11 | 2026-08-04 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | University of Washington | 141 | 2021-05-17 | 2026-01-09 |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2020-11-03 | 2026-06-11 |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-10-14 | 2026-10-07 |
| Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2020-08-04 | 2026-09-18 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 98 | 2020-07-29 | 2026-09-28 |
| Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Apalutamide - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 7 | 2020-05-11 | 2026-07-15 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-06 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 89 | 2017-03-30 | 2026-08-28 |
| Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Bone Scan, Cisplatin, Clinical Observation - EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 924 | 2014-07-01 | 2026-10-13 |
Central Nervous System Neoplasms (4) · Ependymoma (4) · Glioma (4) · Hepatoblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Lymphoma, Non-Hodgkin (4) · Medulloblastoma (4) · Neuroblastoma (4) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Prostatic Neoplasms (4) · Rhabdoid Tumor (4) · Wilms Tumor (4) · Osteosarcoma (3) · Rhabdomyosarcoma (3) · Sarcoma (3)
National Cancer Institute (NCI) (14) · NRG Oncology (2) · OHSU Knight Cancer Institute (1) · University of Washington (1)
United States (18) · Puerto Rico (7) · Canada (5) · Australia (3) · China (1) · Hong Kong (1) · Singapore (1) · Taiwan (1)
Alexander N Shoushtari (1) · Alice Lee (1) · Andrea B Apolo (1) · Ardaman Shergill (1) · Benjamin L Maughan (1) · Bridget F Koontz (1) · Delphine L. Chen, M.D. (1) · Donald W Parsons (1) · Geoffrey I Shapiro (1) · Julie Graff, MD (1) · Katherine A Janeway (1) · Matthew Ingham (1) · Meredith S Irwin (1) · Nancy Y Lee (1) · Patricia M LoRusso (1)
PMID 31401903, PMID 33591402, PMID 33604999, PMID 34486544, PMID 35353553, PMID 39938471, PMID 41166674, PMID 42507969, PMID 42686334
U10CA180821 (5), U10CA180886 (4), U10CA180868 (2), UM1CA186644 (2), UM1CA186689 (2), U10CA021661 (1), U10CA180888 (1), UM1CA081457 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186691 (1), UM1CA186704 (1), UM1CA186709 (1), UM1CA186716 (1), ZIABC011078 (1)